Endocrinology · Internal Medicine · Public Health · 8 h ago
Two Charged in Alleged Counterfeit Ozempic Distribution Scheme Following FDA Investigation
Federal prosecutors announced conspiracy and smuggling charges against two Indian nationals over an alleged counterfeit Ozempic distribution scheme. According to court documents, distribution continued after an FDA seizure and public warning in December 2023.
- Two individuals face conspiracy and smuggling charges involving counterfeit Ozempic.
- Alleged distribution continued after the FDA’s December 2023 public warning.
- The FDA encourages reporting suspected counterfeit medicines and sellers.
- No product-testing results or patient outcomes were reported.
Federal prosecutors announced conspiracy and smuggling charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, in connection with an alleged transnational counterfeit prescription drug distribution scheme. The FDA’s Office of Criminal Investigations assisted in the investigation, which concerned counterfeit Ozempic allegedly obtained from unauthorized sources in China between July 2023 and April 2024.
According to court documents, the products included counterfeit packaging, package inserts, pen labels, and needles intended to deceive downstream customers, including pharmacies and patients, into believing they were receiving authentic, manufacturer-authorized Ozempic. The indictment alleges that the defendants and their co-conspirators sold the products at deeply discounted prices to other co-conspirators and U.S. distributors. Distribution allegedly continued after the FDA’s December 2023 seizure and public warning.
The FDA began issuing public safety alerts about counterfeit Ozempic in December 2023 and encourages reporting suspected counterfeit products and sellers through its reporting system. The announcement does not provide product-testing results, distribution volumes, or patient outcomes. The charges are allegations, and the defendants are presumed innocent unless proven guilty beyond a reasonable doubt.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
U.S. Food and Drug Administration: FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.